Brief: Innovent Biologics Enters Global Strategic Collaboration With Pfizer For 12 Oncology Programs
29/05/2026 02:27
BRIEF-Innovent Biologics Enters Global Strategic Collaboration With Pfizer For 12 Oncology Programs May 29 (Reuters) - Innovent Biologics Inc 1801.HK:
ENTERS GLOBAL STRATEGIC COLLABORATION WITH PFIZER FOR 12 ONCOLOGY PROGRAMS
TO RECEIVE $650 MILLION UPFRONT, DEAL VALUE UP TO $10.5 BILLION
TO RECEIVE UP TO DOUBLE-DIGIT ROYALTIES ON SALES OF APPROVED PRODUCTS
Further company coverage: 1801.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials